Literature DB >> 18061822

Recognition and management of diabetic neuropathy.

Jeff Unger1, B Eliot Cole.   

Abstract

Pain and disability associated with diabetic neuropathy have economic, social, and emotional consequences. Because these complications impact patients during the prime of their lives, physicians should screen and manage patients at risk. Improvement in glycemic and lipid management, glycemic variability, and lifestyle interventions such as smoking cessation should limit disease progression. Patients who have symptomatic disease should be treated, targeting a 50% improvement in pain within 4 weeks. Physicians should also strive to improve function and comorbidities such as sleep disorders, depression, and anxiety. Patient education is critical for treatment adherence and prevention of serious complications. Consequences associated with diabetic neuropathy include nontraumatic amputations and silent ischemia; thus proper foot care and education regarding "warning signs" of silent ischemia are necessary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18061822     DOI: 10.1016/j.pop.2007.07.003

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  2 in total

1.  Effects of Semelil (ANGIPARS™) on diabetic peripheral neuropathy: A randomized, double-blind Placebo-controlled clinical trial.

Authors:  S Bakhshayeshi; Sp Madani; M Hemmatabadi; R Heshmat; B Larijani
Journal:  Daru       Date:  2011       Impact factor: 3.117

2.  The Need for Improved Management of Painful Diabetic Neuropathy in Primary Care.

Authors:  Teresa Sobhy
Journal:  Pain Res Manag       Date:  2016-03-02       Impact factor: 3.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.